Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 6, 2024
Distillery Therapeutics

Inhibiting NLRC5 for hemolytic and inflammatory diseases

BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As interest in NLRP3 grows, biotechs are looking to the next crop of inflammasome targets
BioCentury | Mar 21, 2017
Distillery Therapeutics

Autoimmune disease; gastrointestinal

BioCentury | Dec 8, 2011
Distillery Therapeutics

Indication: Various

Items per page:
1 - 4 of 4